Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy
- 1 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (9) , 1846-1854
Abstract
Background. Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy butKeywords
This publication has 24 references indexed in Scilit:
- Outcomes of Obstetric Hospitalizations Among Women With Inflammatory Bowel Disease in the United StatesClinical Gastroenterology and Hepatology, 2009
- Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Large Community-Based Study From Northern CaliforniaGastroenterology, 2007
- A meta-analysis on the influence of inflammatory bowel disease on pregnancyGut, 2006
- Increasing Incidences of Inflammatory Bowel Disease and Decreasing Surgery Rates in Copenhagen City and County, 2003–2005: A Population-Based Study from the Danish Crohn Colitis DatabaseAmerican Journal of Gastroenterology, 2006
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Management of Crohn's disease in adultsAmerican Journal of Gastroenterology, 2001
- Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registriesAmerican Journal of Gastroenterology, 1998
- Pregnancy outcomes in women with inflammatory bowel disease—A population-based cohort studyAmerican Journal of Obstetrics and Gynecology, 1997
- Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD).Gut, 1996
- Increased risk of preterm birth for women with inflammatory bowel diseaseGastroenterology, 1990